A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7000 participants.
Also called NCT07753993
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,000 participants
- Sponsor
- Registry
-
NCT07753993 -
2025-523994-41-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Indonesia, Israel, Italy, Japan, Malaysia, Mexico, Norway, Peru, Philippines, Poland, Romania, Serbia, South Korea, Spain, Sweden, Taiwan, Thailand, Ukraine, United Arab Emirates, United Kingdom, Vietnam
- Registry status
- Recruiting
Technical summary
Registry record NCT07753993. Randomized; quadruple masking; primary purpose treatment. Start 2026-08-21 (actual); primary completion 2030-10-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.
- Acronym
- Elevate-CKD
- Condition
- Chronic Kidney Disease
- Intervention (Drug)
- Elecoglipron
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct07753993- Content hash
bd2cc2d7a6465119e1dfad0f8e67815a6f9d32f501feed8867a618882c79530a